MARK3 Antibody (YA3922)

MARK3 (microtubule affinity-regulating kinase 3) functions as a serine/threonine kinase that regulates cell cycle progression, cytoskeletal dynamics, and stress-response signaling^[2][19]. Mechanistically, MARK3 phosphorylates microtubule-associated proteins, thereby modulating microtubule stability and intracellular transport, particularly during mitosis and cellular polarization^[2][19]. This kinase influences the Hippo signaling cascade, acting as a negative regulator of LATS1/2 and promoting YAP/TAZ nuclear localization, which is critical for cell proliferation and survival^[2]. In disease models, MARK3 activity has been implicated in oncogenesis, with overexpression enhancing tumor growth, while knockdown reduces cancer cell proliferation^[2][19]. Compared with related isoforms MARK1 and MARK4, MARK3 exhibits distinct substrate specificity and tissue expression patterns, which provide opportunities for isoform-selective intervention^[2]. Small-molecule inhibitors targeting MARK3 have shown potential in reducing hyperproliferation in cancer models, whereas selective agonists remain underexplored due to limited structural characterization^[2][19]. Experimentally, MARK3 modulation is employed to study cytoskeletal remodeling, stress responses, and cell cycle checkpoints, supporting its utility in both cancer biology and neurodegenerative research^[2][19]. Therefore, understanding MARK3’s isoform-specific roles and its regulation of microtubule-associated pathways is essential for designing targeted therapeutic strategies and experimental models.